{
  "chapter_title": "Business Activities",
  "section_title": "Industry",
  "description": "Sector classification and position within the industry.",
  "questions": [
    {
      "question": "How does Ion Beam Applications SA's position in the industry affect its risk profile?",
      "queries": [
        {
          "query": "Ion Beam Applications SA industry classification",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "company position in ion beam technology industry",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "industry risk profile factors for Ion Beam Applications SA",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the key sectoral trends that impact Ion Beam Applications SA's creditworthiness?",
      "queries": [
        {
          "query": "sectoral trends affecting ion beam applications sa credit",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "creditworthiness factors in high-tech manufacturing industry",
          "results": [
            {
              "text": "ose \ncooperation with the Groups operating units. Credit risk \nThe Group has exposure to credit risk. In order \nto cover this risk, the Company policy for \nequipment contracts is to have confirmed letters \nof credit issued by its customers prior to \nshipment of the equipment, or to contract a \nspecific credit insurance from either the Belgian \nofficial export credit agency Credendo or private \ninsurers. Besides, the consolidated financial statements \npresents the financial assets and the financial \nliabilities of the Group by valuation method (fair \nvalue and carrying amount).",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "key drivers of financial performance for ion beam companies",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "How does Ion Beam Applications SA's business model influence its risk exposure?",
      "queries": [
        {
          "query": "ion beam applications sa business model analysis",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "risk exposure factors in ion beam technology business",
          "results": [
            {
              "text": "assessing \nperformance of the operating segments. On the basis of its internal financial reports and given the Groups primary source \nof risk and profitability, IBA has identified two operating segments: - \nProton therapy and other accelerators: This segment constitutes the technological basis of the Groups many \nbusinesses and encompasses development, fabrication, and services associated with medical and industrial \nparticle accelerators and proton therapy systems. - \nDosimetry: This segment in",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "business model innovation and creditworthiness in high-tech industry",
          "results": [
            {
              "text": "nificant impact over several \naccounting periods. On the other hand, the lead \ntime for fulfilling orders gives the Company a \ngood view of its level of activity several months \nin advance. Inventory risk \nInventory includes high technology parts and \ncomponents subject to rapid technological \nobsolescence. Inventory support production but \nalso spare parts to support our customers. IBA \noptimizes the level of inventory required for \nproduction and support on sites for our \ncustomers under a maintenance contract.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the regulatory requirements for Ion Beam Applications SA's sector, and how might they impact its risk profile?",
      "queries": [
        {
          "query": "regulatory requirements for ion beam applications sa",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "industry regulations affecting credit risk for ion beam companies",
          "results": [
            {
              "text": "ESEF requirements under the Delegated Regulation. Based on our procedures performed, we believe that the format of and marking of information in the \ndigital consolidated financial statements included in the annual financial report of Ion Beam Application \nper 31 December 2023 comply in all material respects with the ESEF requirements under the \nDelegated Regulation. Other statements",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "compliance risks in high-tech manufacturing industry",
          "results": [
            {
              "text": "uests close interactions with all those \nvendors. Quality risk / consumer protection / \nproduct safety risk \nIBA is required to comply with quality standards \nin the manufacture of its medical devices and is \nsubject to the supervision of various national \nauthorities. Conditions imposed by such national \nregulatory authorities could result in product \nrecalls or a temporary ban on products. This \ncould have an impact on IBAs reputation, customer satisfaction, and could lead to financial \nlosses. Errors or accidents could arise from the \noperation of our products.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    }
  ]
}